28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Abnormal accumulation of tau proteins in the brain is a hallmark of neurodegenerative diseases such as Alzheimer's disease and is closely linked with neuronal cell death. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Second-generation anti-amyloid therapies (ATTs) offer new options for early Alzheimer's disease treatment, but with modest efficacy and documented adverse events. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Tirzepatide (TRZ) is a dual agonist of glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) receptors that were recently approved for the treatment of type 2 diabetes (T2D) and obesity. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Glucagon-like peptide-1 (GLP-1) receptor agonists (GRA) belong to a class of compounds that reduce blood glucose and energy intake by simulating actions of endogenous incretin hormone GLP-1 after it is released by the gut following food consumption. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, orforglipron and semaglutide are glucagon-like peptide‑1 (GLP-1) receptor agonists. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has transformed the treatment landscape for type 2 diabetes and obesity due to its robust efficacy and wide-ranging therapeutic benefits. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), stroke, and depression, are marked by progressive neuronal dysfunction and loss, yet current treatments remain largely symptomatic with limited disease-modifying efficacy. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Type 2 Diabetes Mellitus therapy has evolved over the years to now include a new class of therapeutics, semaglutide. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Behavioral analyses on APP/PS1 mice demonstrated that Semaglutide improved the cognitive capabilities, particularly in the learning and memory domains. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
GLP-1 receptor agonists (GLP-1RAs), initially approved for diabetes and obesity, are now under investigation for neuroprotective effects in a range of neurological disorders. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Semaglutide reduced body weight and improved glucose tolerance in 12-month-old male and female 5XFAD and APP/PS1 mice, consistent with pharmacological engagement of the GLP-1R. Nevertheless, amyloid plaque density was not different in the cerebral cortex, hippocampus, or subiculum of semaglutide-treated 12-month-old 5XFAD and APP/PS1 mice. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A recent phase III trial testing exendin-4 did not show an improvement, which may be linked to the lack of insulin desensitization in the study participants. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Semaglutide significantly improved motor coordination in rTg4510 mice on the pole test, though not rotarod endurance. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
There is a steadily increasing global burden of neurodegenerative diseases (NDs) such as dementia, including Alzheimer's disease (AD), and movement disorders like Parkinson's disease (PD), which emphasizes the importance of disease-modifying therapy (as opposed to symptomatic therapy). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent guidance from the American Society of Anesthesiologists demonstrates the importance of tailored management of GLP-RA drugs for surgical patients. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease is a devastating neurodegenerative condition that exerts a significant global burden. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Glucagon-like peptide-1 (GLP-1)-based drugs have been approved by the United States Food and Drug Administration (FDA) and are widely used to treat type 2 diabetes mellitus (T2DM) and obesity. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The last two decades have proffered many remarkable choices in managing type 1 and type 2 diabetes mellitus. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
While mitochondria provide critical energy resources, mitochondrial dysfunction can lead to both metabolic and neurodegenerative disorders. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
With this notice, the Internation Journal of Molecular Sciences Editorial Office states their awareness of the concerns regarding the integrity of a number of the figures published within this publication [...]. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer disease is a progressive, neurodegenerative disorder characterized by the accumulation of amyloid beta plaques and hyperphosphorylated tau proteins. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Among persons diagnosed with ADRD or related symptoms, 33.3% used an approved drug over the study period. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The prevalence of neurocognitive disorders (NCD) increases every year as the population continues to age, leading to significant global health concerns. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
TTSs present some limit factors in terms of absorption due to skin physiology and the size of the molecules with established limits of percutaneous penetration (molecular mass of 500 g/mol and log P of 5). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
10 of the 3,106 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →